RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Neurology (clinical),Neurology,Oncology
Link
http://link.springer.com/article/10.1007/s11060-018-03010-0/fulltext.html
Reference50 articles.
1. Gnjatic S, Bronte V, Brunet LR et al (2017) Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer 5:44
2. Ladomersky E, Zhai L, Lenzen A et al (2018) IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clin Cancer Res 24(11):2559–2573
3. Reardon DA, Gokhale PC, Klein SR et al (2016) Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res 4(2):124–135
4. Reardon DA (2017) Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro Oncol 19(suppl_3):iii21
5. Bouffet E, Larouche V, Campbell BB et al (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34(19):2206–2211
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Machine Learning Identification of Immunotherapy Targets in Low-Grade Glioma Using RNA Sequencing Expression Data;World Neurosurgery;2022-07
2. Glioma stem cells and their microenvironment: A narrative review on docking and transformation;Glioma;2022
3. Transcriptomic analysis of glioblastoma multiforme providing new insights into GPR17 signaling communication;Journal of Biomolecular Structure and Dynamics;2020-11-03
4. Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple‑negative breast cancer treated with immune checkpoint inhibitors;Oncology Letters;2020-02-10
5. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers;Translational Lung Cancer Research;2019-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3